Skip to main content Accessibility help
×
Home

The Use of a Combination Antibiogram to Assist with the Selection of Appropriate Antimicrobial Therapy for Carbapenemase-Producing Enterobacteriaceae Infections

  • Alice J. Hsu (a1), Karen C. Carroll (a2), Aaron M. Milstone (a3), Edina Avdic (a1), Sara E. Cosgrove (a4), Mercedes Vilasoa (a5) and Pranita D. Tamma (a3)...

Abstract

Combination antibiograms can be used to evaluate organism cross-resistance among multiple antibiotics. As combination therapy is generally favored for the treatment of carbapenemase-producing Enterobacteriaceae (CPE), combination antibiograms provide valuable information about the combination of antibiotics that achieve the highest likelihood of adequate antibiotic coverage against CPE.

Infect. Control Hosp. Epidemiol. 2015;36(12):1458–1460

Copyright

Corresponding author

Address correspondence to Pranita D. Tamma, MD, MHS, The Johns Hopkins University School of Medicine, Department of Pediatrics, Division of Infectious Diseases, 200 North Wolfe Street, Suite 3155, Baltimore, Maryland 21287 (ptamma1@jhmi.edu).

References

Hide All
1. Tzouvelekis, LS, Markogiannakis, A, Piperaki, E, Souli, M, Daikos, GL. Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect 2014;20:862872.
2. Pogue, JM, Alaniz, C, Carver, PL, Pleva, M, Newton, D, DePestel, DD. Role of unit-specific combination antibiograms for improving the selection of appropriate empiric therapy for Gram-negative pneumonia. Infect Cont Hosp Epidemiol 2011;32:289292.
3. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; approved standard. Twenty-fourth informational supplement. CLSI Document M100-S24. Wayne, PA: CLSI 2014.
4. Roberts, JA, Kirkpatrick, CM, Roberts, MS, Robertson, TA, Dalley, AJ, Lipman, J. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 2009;64:142150.
5. Daikos, GL, Panagiotakopoulou, A, Tzelepi, E, Loli, A, Tzouvelekis, LS, Miriagou, V. Activity of imipenem against VIM-1 metallo-beta-lactamase-producing Klebsiella pneumoniae in the murine thigh infection model. Clin Micro Infect 2007;13:202205.
6. Souli, M, Konstantinidou, E, Tzepi, I, et al. Efficacy of carbapenems against a metallo-beta-lactamase-producing Escherichia coli clinical isolate in a rabbit intra-abdominal abscess model. J Antimicrob Chemother 2011;66:611617.
7. Daikos, GL, Markogiannakis, A. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? Clin Microbiol Infect 2011;17:11351141.
8. Keel, RA, Sutherland, CA, Crandon, JL, Nicolau, DP. Stability of doripenem, imipenem and meropenem at elevated room temperatures. Int J Antimicrob Agents 2011;37:184185.
9. Yahav, D, Lador, A, Paul, M, Leibovici, L. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother 2011;66:19631971.
10. Garonzik, SM, Li, J, Thamlikitkul, V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011;55:32843294.

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed